Comparing In Vitro Spheroids and In Vivo Patient Derived Xenografts (PDXs) to Predict Treatment Responses
Ovarian cancer is the most lethal gynecologic malignancy. Majority of patients develop resistance to standard chemotherapeutic agents, necessitating both new treatments and approaches to predict response to therapy. Our goal is to create improved in vitro and in vivo models in order to predict patient responses to individualized treatments more efficiently, by integrating physiologically relevant spheroid with PDXs. Primary ovarian tumors will be transplanted into mice to establish PDX mouse colonies. Matching histology will be confirmed between PDXs and the primary patient tumors. Small cell number spheroids from both primary tumors and PDXs will be established. Whole exome and RNA sequencing will be performed to identify potential genetic alterations susceptible to targeted therapies. Response to therapy with these agents and standard chemotherapeutics will be determined in the spheroids and the PDXs. Potential biomarkers of response from the sequencing data will be investigated.